Experimental Drug Reduced Visceral Fat in Human Trials
Researchers found that the drug CBL-514 successfully decreased hidden abdominal fat in a recent phase 2 study.
Updated on Oct. 7, 2026 in Weight Loss
Live Poll
Do you trust pharmaceutical treatments to safely and effectively improve your long-term health and weight?
An experimental injection called CBL-514 demonstrated the ability to reduce visceral fat in human participants during two phase 2 clinical trials. Findings from the research were recently presented at the European Association for the Study of Diabetes annual meeting.
Why it matters
The study investigated whether the drug could effectively target hidden fat deposits surrounding vital organs, which are often linked to significant metabolic health risks. These results offer a potential new medical pathway for treating obesity and related conditions.
In a 40-participant study, those receiving up to 600 milligrams of CBL-514 saw an average visceral fat reduction of 12.01%, compared to a 5.68% increase in the placebo group. Researchers noted that 69.6% of participants lost 150 milliliters of subcutaneous fat.
The players
European Association for the Study of Diabetes
This is a non-profit organization dedicated to the support of medical research and the advancement of knowledge in the field of diabetes.
CBL-514
This is an experimental drug designed to trigger apoptosis, or programmed cell death, specifically in fat cells.
The details
Participants received injections into the lower abdomen every three weeks for up to 12 weeks. While injection site reactions like pain, swelling, and redness were reported, no serious adverse events occurred during the trials.
Timeline
Research findings were presented at the EASD annual meeting from September 28 to October 2, 2026.
First results from phase 3 trials are expected by the end of 2027.
The Big Picture
This research follows a pattern set by the European Association for the Study of Diabetes annual meeting as a venue for disseminating new pharmacological breakthroughs. It marks a departure from traditional systemic weight loss drugs by focusing on targeted, localized visceral fat reduction.
Patients should note that CBL-514 is an experimental treatment and is not currently available for public clinical use. Future developments may offer a new, non-surgical option for managing visceral fat, though safety and long-term health impacts remain under evaluation.
The takeaway
This study highlights the potential for localized medical interventions to address visceral fat deposits around organs. While promising, the transition from phase 2 trials to widespread clinical application requires extensive further study.
What happens next
Researchers are currently recruiting participants for two phase 3 trials, with initial results anticipated by the end of 2027.
Further reading
For additional context on the latest developments in pharmacological treatment, visit our Weight Loss section.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Do you trust pharmaceutical treatments to safely and effectively improve your long-term health and weight?
